[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349826-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349826-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","purinergic-signal-transduction-and-metabolic-regulation-by-entpd5-and-entpd6","Purinergic signal transduction and metabolic regulation by ENTPD5 and ENTPD6","","Reviewing purinergic signal transduction and metabolic regulation, this article focuses on the understudied ectoenzymes ENTPD5 and ENTPD6, members of the CD39-ectonucleoside triphosphate diphosphohydrolase family. It summarizes shared molecular structures and how these enzymes modulate purinergic signaling. Evidence is compared across tissue and organelle expression patterns, highlighting links to cellular energy, metabolism, and cancer relevance. Conflicting findings from experimental animal models are assessed, alongside proposals for future clinical applications.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/purinergic-signal-transduction-and-metabolic-regulation-by-entpd5-and-entpd6/349826/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/purinergic-signal-transduction-and-metabolic-regulation-by-entpd5-and-entpd6/349826.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are ENTPD5 and ENTPD6 and where are they expressed?","Question",{"text":63,"@type":64},"ENTPD5 and ENTPD6 are ectonucleoside triphosphate diphosphohydrolases (CD39-ENTPD family members). ENTPD5 is associated with the ER luminal side and ENTPD6 with the Golgi apparatus luminal side, with enzyme release also possible in soluble form.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do ENTPD5 and ENTPD6 influence purinergic signaling and metabolism?",{"text":68,"@type":64},"They modulate purinergic signaling through extracellular nucleotide metabolism. They are also implicated in regulating UDP and related nucleotide-sugar levels, thereby affecting glycosylation-related nucleotide processing and cellular metabolism.",{"name":70,"@type":61,"acceptedAnswer":71},"What is known about ENTPD5 and ENTPD6 in cancer?",{"text":72,"@type":64},"ENTPD5 is abnormally overexpressed in several malignancies and is proposed to promote protein glycosylation and folding, supporting cancer cell survival and proliferation. In contrast, ENTPD6 shows relatively stable expression across tissues, with specific cancer roles described as unclear.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349826,1791179585,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 28 January 2026  \nDOI 10.3389/fendo.2026.1680378  \nOPEN ACCESS  \nEDITED BY  \nCharles Elias Assmann,  \nFederal University of Santa Maria, Brazil  \nREVIEWED BY  \nMichele Zanoni,  \nScientiﬁc Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy Massimo Zollo,  \nUniversity of Naples Federico II, Italy Rajakrishnan Veluthakal,  \nCity of Hope National Medical Center, United States  \n*CORRESPONDENCE  \nSimon C. Robson  \n [srobson@bidmc.harvard.edu](srobson@bidmc.harvard.edu)[ ](srobson@bidmc.harvard.edu)Wenyi Wei  \n [wwei2@bidmc.harvard.edu](wwei2@bidmc.harvard.edu)  \n†These authors have contributed equally to this work  \nRECEIVED 05 August 2025  \nREVISED 29 December 2025  \nACCEPTED 09 January 2026  \nPUBLISHED 28 January 2026  \nCITATION  \nQi Y, Li X, Song X, Wei W, Ghiran I and Robson SC (2026) Purinergic signal transduction and metabolic regulation by ENTPD5 and ENTPD6 .  \nFront. Endocrinol. 17:1680378 .  \ndoi: 10.3389/fendo.2026.1680378  \nCOPYRIGHT  \n© 2026 Qi, Li, Song, Wei, Ghiran and Robson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPurinergic signal transduction and metabolic regulation by ENTPD5 and ENTPD6  \nYihang Qi 1†, Xuefei Li 1,2†, Xinyu Song 1,3, Wenyi Wei 4*, Ionita Ghiran 1 and Simon C. Robson 1*  \n1Center for Inﬂammation Research, Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States, 2 Department of Anesthesiology, Jiangsu Province Hospital of Chinese Medicine, Afﬁliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China, 3 Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China, 4 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States  \nENTPD5 and ENTPD6 are members of the CD39-ectonucleoside triphosphate diphosphohydrolase (CD39-ENTPD) family, which play an important role in modulating the purinergic signaling pathway. Most of the knowledge in this area has been obtained by studying CD39/ENTPD1, the prototype member of this family, and evaluating the translational potential by either treating inﬂammation directly with recombinant proteins or by using antagonists toelicit immune responses in cancer . ENTPD5 and ENTPD6, “orphan-type”ectonucleotidases, are understudied to date, although both are expressed at high levels in various tissues, where they appear involved in regulating signal transduction, cellular energy, and metabolism . ENTPD5 is abnormally overexpressed in several types of malignancies, including prostate, liver, lung, and ovarian cancers. ENTPD5 appears to promote protein glycosylation and folding in part by regulating UDP and UMP levels, thereby enhancing the survival and proliferation of somatic or cancer cells. As such, ENTPD5 has been considered a potential proto-oncogene and a therapeutic target in cancer treatment. In contrast, despite comparable functionality, the related ENTPD6 shows relatively stable expression across tissues in both normal and pathological conditions, with speciﬁc roles in cancer yet unclear. This review provides a comprehensive overview of these two understudied ectoenzymes, detailing their shared molecular structures and control of purinergic signal transduction. In addition, we explore different patterns of tissue and organelle expression of these ecto-enzymes and propose relevance to the modulation of cellular metabolism, as would be important in cancer. We review the sometimes conﬂicting evidence from experimental animal models ","cbCaiq8yHNlqmOIZ","https://ap.wps.com/l/cbCaiq8yHNlqmOIZ","pdf",1744783,17,"English","# Introduction\n## ENTPDase family overview\n## Distinct roles of ENTPD5 and ENTPD6","[{\"question\":\"What are ENTPD5 and ENTPD6 and where are they expressed?\",\"answer\":\"ENTPD5 and ENTPD6 are ectonucleoside triphosphate diphosphohydrolases (CD39-ENTPD family members). ENTPD5 is associated with the ER luminal side and ENTPD6 with the Golgi apparatus luminal side, with enzyme release also possible in soluble form.\"},{\"question\":\"How do ENTPD5 and ENTPD6 influence purinergic signaling and metabolism?\",\"answer\":\"They modulate purinergic signaling through extracellular nucleotide metabolism. They are also implicated in regulating UDP and related nucleotide-sugar levels, thereby affecting glycosylation-related nucleotide processing and cellular metabolism.\"},{\"question\":\"What is known about ENTPD5 and ENTPD6 in cancer?\",\"answer\":\"ENTPD5 is abnormally overexpressed in several malignancies and is proposed to promote protein glycosylation and folding, supporting cancer cell survival and proliferation. In contrast, ENTPD6 shows relatively stable expression across tissues, with specific cancer roles described as unclear.\"}]","Purinergic signal transduction and metabolic regulation by ENTPD5 and ENTPD6 | PDF",1790085825,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdffb5480f9229eec785a2367daac689.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b330ca60b20b19d81a30c2de6c2ddf54.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fd1da315ee0d54997b3ed56197547e7.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2ade3e2444ef8bfee02cbc39e015593.webp",980,1385]